Ipralev (ipratropium/levosalbutamol) / Neutec - LARVOL DELTA

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - P3 | N=74 | Active, not recruiting | Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Head-to-Head • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - P3 | N=74 | Not yet recruiting | Sponsor: Neutec Ar-Ge San ve Tic A.Ş

Head-to-Head • New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - P3 | N=74 | Recruiting | Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Active, not recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - P3 | N=74 | Active, not recruiting | Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Mar 2024 | Trial primary completion date: Jun 2024 ➔ Feb 2024

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - P3 | N=74 | Not yet recruiting | Sponsor: Neutec Ar-Ge San ve Tic A.Ş

Head-to-Head • New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD (clinicaltrials.gov) - P3; N=0; Withdrawn; Sponsor: Neutec Ar-Ge San ve Tic A.Ş; N=102 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD (clinicaltrials.gov) - P3; N=102; Not yet recruiting; Sponsor: Neutec Ar-Ge San ve Tic A.Ş; Trial completion date: Sep 2021 ➔ Sep 2022; Initiation date: Sep 2020 ➔ Sep 2021; Trial primary completion date: Sep 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases